September 2022

What’s New at IIVS – Sept. 2022

September 14, 2022
Dr. Dan Bagley joins the IIVS Board of Directors; President of IIVS Recognized with Award by PCRM; Award for IIVS Training on Alternative Methods IIVS Toxicologist Dr. Argel Islas-Robles participated last week as speaker on the “In Vitro Science Webinars Series” focusing on the topic of non-Animal Methods for dermal and ocular testing on personal care and cosmetics (presentation in Spanish). This was first in a series of events designed to highlight New Approach Methodologies (NAMs) for human and environmental safety without the...

IIVS Toxicologist Presents on Safety Testing in Latin America

September 1, 2022
IIVS Toxicologist Dr. Argel Islas-Robles participated last week as speaker on the “In Vitro Science Webinars Series" focusing on the topic of non-Animal Methods for dermal and ocular testing on personal care and cosmetics (presentation in Spanish). This was first in a series of events designed to highlight New Approach Methodologies (NAMs) for human and environmental safety without the use of animal experimentation in Latin America. Watch the full video here: https://www.youtube.com/watch?v=9f9ub6Httls:   El Toxicólogo de IIVS, Dr. Argel Islas-Robles, participó la semana...

IIVS is Pleased to Announce the Co-Publication of Two Articles

August 25, 2022
IIVS is pleased to announce the co-publication of 2 articles covering the characterization and recommendations for non-animal techniques used to model mucociliary clearance in human-derived test systems and the dosimetry of tobacco products for in vitro testing. Key Challenges for In Vitro Testing of Tobacco Products for Regulatory applications: Recommendations for Dosimetry Ciliary Beat Frequency: Proceedings and Recommendations from a Multi-laboratory Ring Trial Using 3-D Reconstituted Human Airway Epithelium to Model Mucociliary Clearance...

May 2022 Newsletter

July 1, 2022
The ability to ascertain the maximum limit of a compound that can be applied to the skin without inducing skin sensitization is a critical safety criterion for virtually any risk assessment. Using regression models developed by Givaudan (Kempthal, Switzerland), IIVS is able to perform a computational approach to determine predicted EC3 values (Effective Concentration required to induce a 3-fold upregulation of lymph node cell proliferation) using a combination of OECD approved assays (KeratinoSens, hCLAT, and kDPRA). This value can be used to assess risk for compounds to...

IIVS News and Updates June 2022

July 1, 2022
NEW! Good In Vitro Method Practices (GIVMP) Certification IIVS is pleased to announce our new business-to-business GIVIMP Certification Program created to help laboratories: As an OECD guidance document, GIVIMP sets forth internationally recognized quality standards to help ensure that new in vitro methods are ready for implementation, and to foster confidence in the resulting data for use by industry or regulatory bodies....

Eye Irritation Testing and Beyond

May 18, 2022
If you missed the webinar: Establishing Scientific Confidence in New Approach Methodologies (NAMs): Eye Irritation Testing and Beyond, co-sponsored by the Risk Assessment and In Vitro and Alternative Methods Specialty Sections of SOT, a recording is now posted. Speakers included Hans Raabe (IIVS) and Dr. Amy Clippinger, (PETA International Science Consortium e.V.)....

IIVS Posters at SOT 2022

April 14, 2022
Thank you to all who visited our booth or poster sessions at the 2022 Society of Toxicology annual meeting. If you would like copies of any of the poster presented we now have them available to view online: Compatibility Determination of Alternative Solvents in the human Cell Line Activation Test (h-CLAT) for the Assessment of Skin Sensitization Cryopreservation of Human Precision-Cut Lung Slices Provides an Immune Competent, Pulmonary Test System for “On-Demand” Use Modification in Procedure of the Reconstructed Human EpiDermis (RhE) Phototoxicity Assay Improving...

Evaluating the Use of Predictive Models in Combination with In Vitro Assays

April 11, 2022
IIVS is excited to announce the publication of 2 papers evaluating the use of predictive models in combination with in vitro assays to provide a quantitative assessment of skin sensitization potential. This work is presented Drs. Frank Gerberick (GF3 Consultancy, Chief Scientific Advisor to IIVS) and Andreas Natsch (Senior Research Fellow at Givaudan ) Integrated Skin Sensitization Assessment Based on OECD Methods (I): Deriving a Point of Departure for Risk Assessment Integrated Skin Sensitization Assessment Based on OECD Methods(II): Hazard and Potency...

Use of alternative test methods in a tiered testing approach to address photoirritation potential of fragrance materials

January 3, 2022
Happy New Year! IIVS is pleased to greet 2022 with the announcement of a joint publication with the Research Institute for Fragrance Materials (RIFM) involving the evaluation of photoirritation potential of over 100 compounds. This effort, spanning the course of 7 years, involved a tiered testing approach with the application of 3 OECD test guidelines: TG 101, 432 and the recently accepted 498, which codifies the acceptance of Reconstructed human Epidermis as a model for assessing this endpoint. Read the full...